OTC Markets EXMKT - Delayed Quote USD

Eloxx Pharmaceuticals, Inc. (ELOX)

0.0001

0.0000

(0.00%)

At close: June 5 at 8:00:00 PM EDT

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 and collagen alpha 5 in patients post treatment with ELX-02 Results justify the need to conduct a larger clinical trial of ELX-02 in NMAS to confirm clinical benefit U.S. Food and Drug Administration (FDA) allows for continued dosing of subject

GlobeNewswire 6 months ago

ELOX
0.00%

ALMRY

LBTSF
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates

First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for addi

GlobeNewswire 10 months ago

ALMRY

LBTSF

ELOX
0.00%

Performance Overview

Return	ELOX	S&P 500 (^GSPC)
YTD	--	+2.11%
1-Year	-99.99%	+12.32%
3-Year	-100.00%	+49.48%